Publications

Invitation to investigators

Publications arising from the BADBIR study will be written by "Banner authors" on behalf of the BADBIR "Study Group". The BADBIR Banner authors and Study Group will comprise authors who have:

  • 1) Made a relevant and substantial contribution to conception and design, aquisition of data, or analysis and interpretation of data;
  • 2) Drafted the article or revised it critically for important medical intellectual content;
  • 3) Provided final approval of the version to be published, in accordance with the Uniform Requirements for Manuscripts Submitted for Biomedical Journals.

We wish to recognise the important contributions made by investigators who are not part of the BADBIR Steering Committee. Investigators who have made important contributions to BADBIR, are willing to comply with the three conditions outlined above, and are keen to be involved are encouraged to apply. Applications will be reviewed by the BADBIR Research and Steering Committees. Applicants will then be informed of the committees' decision and relevant feedback will be provided if necessary.

Please send the completed application form to Shehnaz Ahmed, Director of Research and Publishing, British Association of Dermatologists, 4 Fitzroy Square, London, W1T 5HQ. Alternatively the form can be sent by email: shehnaz@bad.org.uk. This must be sent by the date shown in the 'Deadline for applications' section of this page.

Publications

All of the publications based on BADBIR data are listed below. Each one has a link to PubMed where you can read the full details.

# Title Authors Publication Year Journal
1 The British Association of Dermatologists Biologic Interventions Register (BADBIR): Design, Methodology and Objectives Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CE; BADBIR Study Group. Br J Dermatol 2012 2012 Br J Dermatol
2 Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis Sawyer LM, Wonderling D, Jackson K, Murphy R, Samarasekera EJ, Smith CH PharmacoEconomics 2015 2015 PharmacoEconomics
3 Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM; Reynolds NJ; Griffiths CEM; BADBIR Study Group J Invest Dermatol 2015 2015 J Invest Dermatol
4 Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, McElhone K, Lunt M, Barker JN, Burden AD, Ormerod AD, Reynolds NJ; Smith CH; Griffiths CEM. Br J Dermatol 2015 2015 Br J Dermatol
5 Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Iskandar IYK, Ashcroft DM, Warren RB, Evans I, McElhone K, Owen CM, Burden AD, Smith CH, Reynolds NJ, Griffiths CEM Br J Dermatol 2017 2017 Br J Dermatol
6 Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, Reynolds NJ, Griffiths CEM Br J Dermatol 2017 2017 Br J Dermatol
7 Identification of Factors That May Influence the Selection of First-Line Biological Therapy for People With Psoriasis: A Prospective, Multicentre Cohort Study Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD, Smith CH, Payne K, Griffiths CEM Br J Dermatol 2017 2017 Br J Dermatol
8 Differential drug survival of second-line biologic therapies in psoriasis patients: observational cohort study from the British Association of Dermatologists Biologic Interventions Register Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, Smith CH, Reynolds NJ, Ashcroft DM, Griffiths CEM; BADBIR Study Group J Invest Dermatol 2018 2018 J Invest Dermatol
9 Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K; BADBIR Study Group Value Health 2018 2018 Value Health
10 Risk of Serious Infection in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study From the British Association of Dermatologists Biologic Interventions Register (BADBIR) Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group J Invest Dermatol 2018 2018 J Invest Dermatol
11 Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR Mason KJ, Barker J, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group JAMA Dermatology 2018 2018 JAMA Dermatology
12 Cumulative exposure to biologics and risk of cancer in psoriasis patients: a meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland I Garcia-Doval; MA Descalzo; KJ Mason; AD Cohen; AD Ormerod; FJ Gómez-García; S Cazzaniga; I Feldhamer; H Ali; E Herrera-Acosta; CEM Griffiths; R Stern; L Naldi; Psonet Network. Br J Dermatol 2018 2018 Br J Dermatol
13 Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L; BADBIR Study Group; Psoriasis Stratification to Optimise Relevant Therapy Study Groups J Invest Dermatol 2018 2018 J Invest Dermatol
14 Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith CH; PSORT Consortium; BADBIR Study Group Br J Dermatol 2018 2018 Br J Dermatol
15 HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, CEM Griffiths, Smith CH, Simpson MA, Barker JN; BSTOP Study Group; PSORT Consortium. J Allergy Clin Immunol 2019 2019 J Allergy Clin Immunol
16 Infliximab Is Associated With an Increased Risk of Serious Infection in Patients With Psoriasis in the U.K. And Republic of Ireland: Results From the British Association of Dermatologists Biologic Interventions Register (BADBIR) Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BSTOP Study Group Br J Dermatol 2019 2019 Br J Dermatol
17 Development and Validation of a Multivariable Risk Prediction Model for Serious Infection in Patients With Psoriasis Receiving Systemic Therapy Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kühl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BSTOP Study Group Br J Dermatol 2019 2019 Br J Dermatol
18 Persistence and effectiveness of non-biologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM Br J Dermatol 2019 2019 Br J Dermatol
19 Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A; BSTOP Study Group; PSORT Consortium. JAMA Dermatology 2019 2019 JAMA Dermatology
20 A Standardization Approach to Compare Treatment Safety and Effectiveness Outcomes Between Clinical Trials and Real-World Populations in Psoriasis Yiu ZZN, Mason KJ, Barker J, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group Br J Dermatol 2019 2019 Br J Dermatol
21 Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa‐Rajah A; Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Andrew Wright, Griffiths CEM, Reynolds NJ,Barker J, Warren RB, Burden AD, Theo Rispens , Joseph F Standing , Catherine H Smith; BADBIR Study Group; BSTOP Study Group; PSORT Consortium Clin Transl Sci 2020 2020 Clin Transl Sci
22 Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM; BADBIR Study Group J Eur Acad Dermatol Venereol 2020 2020 J Eur Acad Dermatol Venereol
23 Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN; Burden AD, Smith CH; BADBIR study group and the PSORT consortium Br J Dermatol 2020 2020 Br J Dermatol
24 The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group Br J Dermatol 2020 2020 Br J Dermatol
25 Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group Br J Dermatol 2020 2020 Br J Dermatol
26 Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group JAMA Dermatol 2020 2020 JAMA Dermatol
27 Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ; Ormerod AD; BADBIR Study Group JEADV 2021 2021 JEADV
28 Defining Trajectories of Response in Psoriasis Patients Treated with Biologic Therapies Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN; Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium Br J Dermatol 2021 2021 Br J Dermatol
29 Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD JEADV 2021 2021 JEADV
30 Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models Jalali-Najafabadi F, Stadler M, Dand N, Jadon D, Soomro M, Ho P, Marzo-Ortega H, Helliwell P, Korendowych E, Simpson MA, Packham J, Smith CH, Barker JN, McHugh N, Warren RB, Barton A, Bowes J; BADBIR Study Group; BSTOP Study Group. Scientific Reports 2021 Scientific Reports
31 Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group JAMA Dermatol 2022 JAMA Dermatol
32 Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups J Invest Dermatol 2022 J Invest Dermatol